Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Integumen Debt Conversion

1 May 2019 11:00

RNS Number : 7356X
Venn Life Sciences Holdings PLC
01 May 2019
 

1 May 2019

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Integumen plc ("Integumen") Debt Conversion - Related Party Transaction

Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces, that following the approval of Integumen shareholders and under the terms of the Venn Debt Conversion Agreement the debt of £421,000 owed by Integumen, has been converted into 30,071,428 new Integumen ordinary shares at a price of 1.4 pence, conditional upon admission.

Separate to this conversion, Venn has sold 42,244,682 ordinary shares for a total consideration of €575,000. Following Admission of the conversion shares referred to above, Venn will hold 30,071,428 ordinary shares.

Venn has agreed that any disposal of Integumen ordinary shares held by them for the two years following Admission will be effected through Integumens broker so as to ensure an orderly market in the ordinary shares.

The debt conversion is a related party transaction for the purposes of Rule 13 of the AIM Rules for companies. As Tony Richardson is Integumens Chairman, the Chief Executive of Venn, and therefore is not considered to be independent for the purposes of considering and negotiating the Venn Debt Conversion Agreement. The Directors (other than Tony Richardson) consider, having consulted with Arden Partners plc, the Company's nominated adviser, that the terms of the Venn Debt Conversion Agreement and conversion by Venn are fair and reasonable in so far as its Shareholders are concerned.

 

Enquiries:

Venn Life Sciences Holdings plc Tel: +353 1 5499 341Tony Richardson, Chief Executive Officer

Arden Partners plc Tel: +44 (0)2076145900

John Llewellyn-Lloyd, Ruari McGirr, Benjamin Cryer

Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363Fergal Meegan / Matthew de Vere White (Corporate Finance)

 

 

DEFINITIONS

The following words and expressions shall have the following meanings in this document unless the context otherwise requires:

 

"Venn Debt Conversion Agreement"

the agreement dated 11 April 2019 between (1) the Company and (2) Venn to convert the Venn Debt into the Venn Debt Shares

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSSASUFFUSEEI
Date   Source Headline
17th Feb 202212:05 pmRNSPositive results from RSV Human Challenge Study
14th Feb 20227:00 amRNSLaunch of STRiVE project
2nd Feb 20227:00 amRNSWorld’s first COVID-19 Characterisation Study
26th Jan 20224:40 pmRNSSecond Price Monitoring Extn
26th Jan 20224:36 pmRNSPrice Monitoring Extension
20th Jan 20227:00 amRNSMalaria Human Challenge Model Launched
21st Dec 20217:00 amRNS£5m Influenza human challenge study contract win
16th Dec 20214:41 pmRNSSecond Price Monitoring Extn
16th Dec 20214:35 pmRNSPrice Monitoring Extension
10th Dec 202111:05 amRNSSecond Price Monitoring Extn
10th Dec 202111:00 amRNSPrice Monitoring Extension
10th Dec 20217:05 amRNSExercise of Options
10th Dec 20217:00 amRNS$13.4m Influenza HCS contract win
6th Dec 20217:00 amRNSPositive results from Flu Human Challenge Study
19th Nov 20217:00 amRNSImutex Vaccine Phase I Study Results
17th Nov 20217:00 amRNS£5.1m RSV contract
15th Nov 20217:00 amRNS£1.5m Contract renewal for Venn Life Sciences
13th Oct 20217:00 amRNSDirectorate Change
20th Sep 20217:00 amRNSHalf-year Report
20th Sep 20217:00 amRNS£5.7m Influenza human challenge study contract win
9th Sep 20217:00 amRNSNotice of Results
7th Sep 20217:00 amRNSPositive results from RSV Human Challenge Study
24th Aug 20219:05 amRNSSecond Price Monitoring Extn
24th Aug 20219:00 amRNSPrice Monitoring Extension
24th Aug 20217:00 amRNS£8.1m Asthma Human Challenge Study Contract Win
9th Aug 20217:00 amRNSMalaria Human Challenge Model
29th Jul 20217:00 amRNSDNDi Phase II trial support
22nd Jul 20217:00 amRNSNEJM Opinion Piece
21st Jul 202112:58 pmRNSResult of AGM
14th Jul 20219:06 amRNSDirectors’ Dealings
14th Jul 20218:04 amRNSAIM Schedule 1 update by Poolbeg Pharma plc
14th Jul 20217:01 amRNSNew Contract win for Open Orphan’s Breda office
14th Jul 20217:00 amRNSCOVID-19 Human Challenge Programme update
9th Jul 20217:00 amRNSHRV and Flu contract
7th Jul 20214:41 pmRNSSecond Price Monitoring Extn
7th Jul 20214:36 pmRNSPrice Monitoring Extension
30th Jun 20217:00 amRNS2020 Annual Report and 2021 AGM Notice
17th Jun 20217:00 amRNSFinal Results to 31 December 2020
17th Jun 20217:00 amRNSDemerger Update
14th Jun 20217:00 amRNSRe. Distribution in Specie and Notice of Results
11th Jun 20217:00 amRNSExercise of Warrants
19th May 20217:00 amRNSCourt Approval
10th May 20217:15 amRNSExercise of Share Options
10th May 20217:00 amRNS£3m COVID challenge virus manufacturing contract
29th Apr 202111:39 amRNSResult of General Meeting
13th Apr 20217:00 amRNSPotential demerger of certain non-core assets
9th Apr 20217:00 amRNSLaunch of Disease in Motion platform
31st Mar 20217:00 amRNSHolding(s) in Company
26th Mar 20217:00 amRNS£7.5m Human Challenge Study Contract
25th Mar 20217:00 amRNSCOVID-19 Human Challenge Programme update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.